Annual Cash & Cash Equivalents
$389.48 M
+$177.59 M+83.82%
December 31, 2023
Summary
- As of February 7, 2025, CRSP annual cash & cash equivalents is $389.48 million, with the most recent change of +$177.59 million (+83.82%) on December 31, 2023.
- During the last 3 years, CRSP annual cash & cash equivalents has fallen by -$779.14 million (-66.67%).
- CRSP annual cash & cash equivalents is now -66.67% below its all-time high of $1.17 billion, reached on December 31, 2020.
Performance
CRSP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$225.67 M
-$258.80 M-53.42%
September 30, 2024
Summary
- As of February 7, 2025, CRSP quarterly cash and cash equivalents is $225.67 million, with the most recent change of -$258.80 million (-53.42%) on September 30, 2024.
- Over the past year, CRSP quarterly cash and cash equivalents has dropped by -$163.81 million (-42.06%).
- CRSP quarterly cash and cash equivalents is now -86.30% below its all-time high of $1.65 billion, reached on June 30, 2021.
Performance
CRSP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CRSP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +83.8% | -42.1% |
| 3 y3 years | -66.7% | -77.7% |
| 5 y5 years | -14.7% | -64.2% |
CRSP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -57.8% | +83.8% | -75.5% | +6.5% |
| 5 y | 5-year | -66.7% | +83.8% | -86.3% | +6.5% |
| alltime | all time | -66.7% | >+9999.0% | -86.3% | +44.7% |
CRISPR Therapeutics AG Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $225.67 M(-53.4%) |
| Jun 2024 | - | $484.47 M(-31.5%) |
| Mar 2024 | - | $707.43 M(+81.6%) |
| Dec 2023 | $389.48 M(+83.8%) | $389.48 M(-26.2%) |
| Sep 2023 | - | $527.76 M(+18.7%) |
| Jun 2023 | - | $444.80 M(+29.1%) |
| Mar 2023 | - | $344.41 M(+62.5%) |
| Dec 2022 | $211.88 M(-77.0%) | $211.88 M(-57.1%) |
| Sep 2022 | - | $494.15 M(-0.6%) |
| Jun 2022 | - | $496.89 M(-27.3%) |
| Mar 2022 | - | $683.91 M(-25.9%) |
| Dec 2021 | $923.03 M(-21.0%) | $923.03 M(-8.8%) |
| Sep 2021 | - | $1.01 B(-38.6%) |
| Jun 2021 | - | $1.65 B(+46.2%) |
| Mar 2021 | - | $1.13 B(-3.6%) |
| Dec 2020 | $1.17 B | $1.17 B(+12.2%) |
| Sep 2020 | - | $1.04 B(+10.2%) |
| Jun 2020 | - | $945.07 M(+6.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $889.71 M(-5.7%) |
| Dec 2019 | $943.77 M(+106.7%) | $943.77 M(+49.9%) |
| Sep 2019 | - | $629.72 M(+47.2%) |
| Jun 2019 | - | $427.88 M(-2.2%) |
| Mar 2019 | - | $437.55 M(-4.2%) |
| Dec 2018 | $456.65 M(+90.5%) | $456.65 M(-6.3%) |
| Sep 2018 | - | $487.30 M(+52.4%) |
| Jun 2018 | - | $319.74 M(-6.4%) |
| Mar 2018 | - | $341.77 M(+42.5%) |
| Dec 2017 | $239.76 M(-24.0%) | $239.76 M(-5.4%) |
| Sep 2017 | - | $253.52 M(-6.9%) |
| Jun 2017 | - | $272.26 M(-5.7%) |
| Mar 2017 | - | $288.87 M(-8.4%) |
| Dec 2016 | $315.52 M(+102.3%) | $315.52 M(+38.0%) |
| Sep 2016 | - | $228.61 M(-7.4%) |
| Jun 2016 | - | $246.85 M(+58.3%) |
| Dec 2015 | $155.96 M(>+9900.0%) | $155.96 M |
| Dec 2014 | $945.00 K | - |
FAQ
- What is CRISPR Therapeutics AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly cash and cash equivalents year-on-year change?
What is CRISPR Therapeutics AG annual cash & cash equivalents?
The current annual cash & cash equivalents of CRSP is $389.48 M
What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash & cash equivalents is $1.17 B
What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
Over the past year, CRSP annual cash & cash equivalents has changed by +$177.59 M (+83.82%)
What is CRISPR Therapeutics AG quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CRSP is $225.67 M
What is the all time high quarterly cash and cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash and cash equivalents is $1.65 B
What is CRISPR Therapeutics AG quarterly cash and cash equivalents year-on-year change?
Over the past year, CRSP quarterly cash and cash equivalents has changed by -$163.81 M (-42.06%)